Trial · NCT03028766
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
NCT03028766, Phase 1, Completed, University of Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer. Trials, record NCT03028766. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03028766
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
- NCT number
- NCT03028766
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- University of Birmingham
- Conditions
- Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer
- Interventions
- AZD1775, Cisplatin, Radiotherapy
- First posted
- 2017-01-23
- Last updated
- 2024-09-19
- Other registries' IDs
- eudract:2015-003583-37, isrctn:ISRCTN76291951
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended dose(s) of AZD1775 | Group A - Up to 42 days from start of treatment; Group B - Up to 12 weeks from the start of treatment | Group A: The highest safe dose of AZD1775 in combination with cisplatin with a predefined target Dose Limiting Toxicity probability of 25% for up to 42 days from start of treatment. Group B: The maximum tolerated dose of AZD1775 in combination with cisplatin/radiotherapy with a target DLT of 30% for up to 12 weeks from the start of treatment. |
| Primary | Safety profile of AZD1775 for Group A and Group B by reporting of all Adverse Events, Serious Adverse Events, Suspected Unexpected Adverse Reactions, deaths, deviations and withdrawal as assessed by the Safety Committee. | From registration, while on treatment and during follow up periods | Safety profile of AZD1775 in combination with cisplatin in Group A and cisplatin/radiotherapy in Group B. |
| Secondary | Disease-free survival in Groups A and B | Patients will be followed-up clinically for 12 weeks in Group A and for 12 months in Group B. | Disease-free survival is defined as the time from trial entry to date of disease recurrence, progression or patient death until end of follow up period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03028766
GET https://conductscience.org/api/trials/v1/NCT03028766/registered